Search Results

New data from four real-world studies shows the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems.

https://www.seqirus.us/news/new-rwd-presented-options-xi-show-influenza-vaccines-can-reduce-burden-of-seasonal-influenza

This year marks the first full season that Seqirus’ portfolio of innovative influenza vaccines provides a differentiated vaccine option for people of all ages who are eligible in the U.S. to receive a flu shot

https://www.seqirus.us/news/seqirus-begins-shipping-portfolio-of-innovative-influenza-vaccines-for-the-2022-23-us-season

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.us/products

U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has included FLUAD® QUADRIVALENT as a preferentially recommended seasonal influenza vaccine for adults 65 years of age and older.

https://www.seqirus.us/news/fluad-quadrivalent-is-a-preferentially-recommended-influenza-vaccine-for-adults-65-and-older

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.us/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

New data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in Belfast, United Kingdom.

https://www.seqirus.us/news/csl-seqirus-to-highlight-commitment-to-influenza-protection-with-data-presentations-at-options-xi

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news

The new pre-filled syringe line has received FDA approval and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond.

https://www.seqirus.us/news/seqirus-completes-$156-million-expansion-to-hsp-manufacturing-facility

Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based seasonal and pandemic influenza vaccines.

https://www.seqirus.us/news/seqirus-holly-springs-manufacturing-facility-designated-by-us-government-as-pandemic-ready